CoR #203 is Up
Bob Wilson presents a truly remarkable edition of the Cavalcade of Risk at WorkersCompensation.com.
Month: March 2014
Too much competition?
Rarely due consumers think that too much competition is a problem. According to the Centers for Medicare and Medicaid Services (CMS), however, this is a major issue for consumers when they choose Part D prescription drug health plans. Avalere reports that: Proposed revisions to the meaningful differences policy will restrict the market’s top sponsors from…
Quotation of the Day: Pricing of Biosimilars
Bilsimilars are biologic medical products whose active drug substance is made by a living organism or derived from a living organism by means of recombinant DNA or controlled gene expression methods. Biologic drugs can be patented, but once the patents expire, biosimilars can enter the market. Are biosimilars> priced similarly to generics? According to Ana…
Increasing Generalizability of RCTs
Is your randomized controlled trial (RCT) generalizable to the general population? This question is known as external validity and is a major issue for a number of treatments. Sometimes, a treatment is very effective in an RCT, but less so in the real world. One reason why this may be the case is that the…